UK markets closed
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • FTSE 250

    19,363.28
    -46.14 (-0.24%)
     
  • AIM

    853.32
    +2.76 (+0.32%)
     
  • GBP/EUR

    1.1660
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.2296
    +0.0040 (+0.33%)
     
  • BTC-GBP

    13,812.90
    -41.83 (-0.30%)
     
  • CMC Crypto 200

    404.33
    +2.91 (+0.72%)
     
  • S&P 500

    4,071.70
    -4.87 (-0.12%)
     
  • DOW

    34,429.88
    +34.87 (+0.10%)
     
  • CRUDE OIL

    80.34
    -0.88 (-1.08%)
     
  • GOLD FUTURES

    1,811.40
    -3.80 (-0.21%)
     
  • NIKKEI 225

    27,777.90
    -448.18 (-1.59%)
     
  • HANG SENG

    18,675.35
    -61.09 (-0.33%)
     
  • DAX

    14,529.39
    +39.09 (+0.27%)
     
  • CAC 40

    6,742.25
    -11.72 (-0.17%)
     

Global Vaccine Contract Manufacturing Market to Reach $5.6 Billion by 2027

ReportLinker
ReportLinker

In the changed post COVID-19 business landscape, the global market for Vaccine Contract Manufacturing estimated at US$3. 6 Billion in the year 2020, is projected to reach a revised size of US$5. 6 Billion by 2027, growing at a CAGR of 6.

New York, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vaccine Contract Manufacturing Industry" - https://www.reportlinker.com/p06033210/?utm_source=GNW
5% over the analysis period 2020-2027. Attenuated, one of the segments analyzed in the report, is projected to record a 6.3% CAGR and reach US$2.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Inactivated segment is readjusted to a revised 6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $976.8 Million, While China is Forecast to Grow at 11.1% CAGR

The Vaccine Contract Manufacturing market in the U.S. is estimated at US$976.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 11.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$771.8 Million by the year 2027.



Subunit-based Segment to Record 7% CAGR

In the global Subunit-based segment, USA, Canada, Japan, China and Europe will drive the 7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$404.7 Million in the year 2020 will reach a projected size of US$624.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 8.6% CAGR through the analysis period.

Select Competitors (Total 34 Featured) -
Ajinomoto Althea, Inc.
Albany Molecular Research, Inc.
Catalent, Inc.
Cobra Bio
Cytovance Biologics
Fujifilm Diosynth Biotechnologies U.S.A., Inc.
Icon plc
IDT Biologika
KBI Biopharma
Lonza


Read the full report: https://www.reportlinker.com/p06033210/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Vaccine Contract Manufacturing - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Vaccine Contract
Manufacturing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Vaccine Contract
Manufacturing by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Attenuated by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Attenuated by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Attenuated by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Inactivated by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Inactivated by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Inactivated by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Subunit-based by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Subunit-based by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Subunit-based by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Toxoid-based by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Toxoid-based by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Toxoid-based by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
DNA-based by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for DNA-based by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for DNA-based by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Human by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Human by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Human by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Veterinary by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Veterinary by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Veterinary by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 25: World Vaccine Contract Manufacturing Market Analysis
of Annual Sales in US$ Million for Years 2012 through 2027

III. MARKET ANALYSIS

UNITED STATES
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2022
(E)
Table 26: USA Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 27: USA Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 28: USA 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 29: USA Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 30: USA Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 31: USA 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

CANADA
Table 32: Canada Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 33: Canada Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 34: Canada 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 35: Canada Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 36: Canada Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 37: Canada 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

JAPAN
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2022 (E)
Table 38: Japan Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 39: Japan Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 40: Japan 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 41: Japan Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 42: Japan Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 43: Japan 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

CHINA
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2022 (E)
Table 44: China Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 45: China Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 46: China 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 47: China Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 48: China Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 49: China 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

EUROPE
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2022 (E)
Table 50: Europe Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 51: Europe Historic Review for Vaccine Contract
Manufacturing by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 52: Europe 15-Year Perspective for Vaccine Contract
Manufacturing by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2021 & 2027

Table 53: Europe Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 54: Europe Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 55: Europe 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 56: Europe Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 57: Europe Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 58: Europe 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

FRANCE
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2022 (E)
Table 59: France Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 60: France Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 61: France 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 62: France Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 63: France Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 64: France 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

GERMANY
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2022 (E)
Table 65: Germany Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 66: Germany Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 67: Germany 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 68: Germany Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 69: Germany Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 70: Germany 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

ITALY
Table 71: Italy Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 72: Italy Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 73: Italy 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 74: Italy Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 75: Italy Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 76: Italy 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

UNITED KINGDOM
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for
2022 (E)
Table 77: UK Recent Past, Current & Future Analysis for Vaccine
Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 78: UK Historic Review for Vaccine Contract Manufacturing
by Vaccine Type - Attenuated, Inactivated, Subunit-based,
Toxoid-based and DNA-based Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 79: UK 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 80: UK Recent Past, Current & Future Analysis for Vaccine
Contract Manufacturing by Application - Human and Veterinary -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 81: UK Historic Review for Vaccine Contract Manufacturing
by Application - Human and Veterinary Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 82: UK 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

SPAIN
Table 83: Spain Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 84: Spain Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 85: Spain 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 86: Spain Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 87: Spain Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 88: Spain 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

RUSSIA
Table 89: Russia Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 90: Russia Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 91: Russia 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 92: Russia Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 93: Russia Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 94: Russia 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

REST OF EUROPE
Table 95: Rest of Europe Recent Past, Current & Future Analysis
for Vaccine Contract Manufacturing by Vaccine Type -
Attenuated, Inactivated, Subunit-based, Toxoid-based and
DNA-based - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 96: Rest of Europe Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 97: Rest of Europe 15-Year Perspective for Vaccine
Contract Manufacturing by Vaccine Type - Percentage Breakdown
of Value Sales for Attenuated, Inactivated, Subunit-based,
Toxoid-based and DNA-based for the Years 2012, 2021 & 2027

Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 99: Rest of Europe Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 100: Rest of Europe 15-Year Perspective for Vaccine
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Human and Veterinary for the Years 2012, 2021 &
2027

ASIA-PACIFIC
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Table 101: Asia-Pacific Recent Past, Current & Future Analysis
for Vaccine Contract Manufacturing by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 102: Asia-Pacific Historic Review for Vaccine Contract
Manufacturing by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 103: Asia-Pacific 15-Year Perspective for Vaccine
Contract Manufacturing by Geographic Region - Percentage
Breakdown of Value Sales for Australia, India, South Korea and
Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027

Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Vaccine Contract Manufacturing by Vaccine Type -
Attenuated, Inactivated, Subunit-based, Toxoid-based and
DNA-based - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 105: Asia-Pacific Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 106: Asia-Pacific 15-Year Perspective for Vaccine
Contract Manufacturing by Vaccine Type - Percentage Breakdown
of Value Sales for Attenuated, Inactivated, Subunit-based,
Toxoid-based and DNA-based for the Years 2012, 2021 & 2027

Table 107: Asia-Pacific Recent Past, Current & Future Analysis
for Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 108: Asia-Pacific Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 109: Asia-Pacific 15-Year Perspective for Vaccine
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Human and Veterinary for the Years 2012, 2021 &
2027

AUSTRALIA
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Australia for 2022 (E)
Table 110: Australia Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 111: Australia Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 112: Australia 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 113: Australia Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 114: Australia Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 115: Australia 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

INDIA
Vaccine Contract Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in India for 2022 (E)
Table 116: India Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Vaccine Type - Attenuated,
Inactivated, Subunit-based, Toxoid-based and DNA-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 117: India Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 118: India 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 119: India Recent Past, Current & Future Analysis for
Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 120: India Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 121: India 15-Year Perspective for Vaccine Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Human and Veterinary for the Years 2012, 2021 & 2027

SOUTH KOREA
Table 122: South Korea Recent Past, Current & Future Analysis
for Vaccine Contract Manufacturing by Vaccine Type -
Attenuated, Inactivated, Subunit-based, Toxoid-based and
DNA-based - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 123: South Korea Historic Review for Vaccine Contract
Manufacturing by Vaccine Type - Attenuated, Inactivated,
Subunit-based, Toxoid-based and DNA-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 124: South Korea 15-Year Perspective for Vaccine Contract
Manufacturing by Vaccine Type - Percentage Breakdown of Value
Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based
and DNA-based for the Years 2012, 2021 & 2027

Table 125: South Korea Recent Past, Current & Future Analysis
for Vaccine Contract Manufacturing by Application - Human and
Veterinary - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 126: South Korea Historic Review for Vaccine Contract
Manufacturing by Application - Human and Veterinary Markets -
Independent Analysis of Annual Sales in US$ Million for Years

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033210/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001